EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study



Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study



Annals of Oncology 13(1): 103-107



Oxaliplatin and vinorelbine are both active agents against non-small-cell lung cancer (NSCLC). In a previous phase I trial, we showed that oxaliplatin (130 mg/m2, day 1) and vinorelbine (26 mg/m2/day, days 1 and 8) can be safely combined when given every 21 days. We completed the evaluation of this new platinum-based doublet in advanced NSCLC patients in a multicenter phase II study. Twenty-eight chemotherapy-naïve patients (22 men and six women: median age 58 years, range 33-70), including 20 with stage IV disease, received this out-patient combination, with 5-hydroxytryptamine-3-receptor agonists as the only prophylactic measure. A total of 117 cycles were given, for a median of three per patient (range 1-8). Of 26 eligible patients, nine achieved a partial response (WHO criteria), giving an objective response rate of 35% [95% confidence interval (CI) 17% to 56%]. The median progression free survival was 5.0 months (95% CI 3.1 to 6.9), median overall survival was 9.8 months (95% CI 2.2 to 17.5) and the 1-year survival rate was 37%. Neutropenia was the principal toxicity, grade 4 occurring in 11 patients (39%) and 25 cycles (22%). Four patients (14%) experienced one episode of febrile neutropenia each. Acute oxaliplatin-related neurosensory toxicity was prevalent, but was mild to moderate in the majority of patients (82%) and reversible. Grade 1/2 vomiting (65% of patients) and diarrhea (32% of patients) were easily managed. The oxaliplatin-vinorelbine doublet is a safe and active out-patient combination. It may represent an interesting alternative in the management of patients with NSCLC, and serve as a new doublet to which other active agents could be added.

(PDF emailed within 0-6 h: $19.90)

Accession: 046899163

Download citation: RISBibTeXText

PMID: 11863089

DOI: 10.1093/annonc/mdf006



Related references

Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study. Anticancer Research 23(2c): 1803-1809, 2003

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Supplement 6): S28, October, 2001

Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 19(2): 458-463, 2001

Vinorelbine (NVB) oral (NVBo) in combination with carboplatin (CBDCA) followed by maintenance therapy with single agent vinorelbine oral in stage III/IV non-small cell lung cancer (NSCLC): Final results of a multicenter international phase II trial. Journal of Clinical Oncology 24(18_suppl): 7126-7126, 2016

Randomly clinical study of vinorelbine/cisplatin and vinorelbine/oxaliplatin regimens in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 9(1): 71-73, 2006

Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. American Journal of Clinical Oncology 21(1): 67-71, 1998

Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study. Lung Cancer 28(3): 237-244, 2000

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology 20(7): 1249-1256, 2009

Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Medica Austriaca 22(5): 120-124, 1995

A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Annals of Oncology 12(10): 1375-1381, 2002

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. Lung Cancer 34 Suppl 4(): S77-S80, 2001

Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21(3): 213-220, 1998

nCombination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: A multicenter phase II study of the Greek Cooperative Group for Lung Cancer. Lung Cancer 21(3): 213-220, 1998

A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer 52(2): 165-171, 2006

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study. Investigational New Drugs 24(3): 241-248, 2005